Invention Grant
- Patent Title: Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
-
Application No.: US16798030Application Date: 2020-02-21
-
Publication No.: US11434296B2Publication Date: 2022-09-06
- Inventor: David Q. Shih , Stephan R. Targan , Dalin Li , Janine Bilsborough
- Applicant: CEDARS-SINAI MEDICAL CENTER
- Applicant Address: US CA Los Angeles
- Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee: CEDARS-SINAI MEDICAL CENTER
- Current Assignee Address: US CA Los Angeles
- Agency: Wilson Sonsini Goodrich & Rosati
- Main IPC: A61K39/395
- IPC: A61K39/395 ; G01N33/53 ; C07K16/28 ; C12Q1/6883 ; C07K16/24 ; A61K45/06 ; C12N15/113 ; G01N33/68
Abstract:
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Information query
